Eisai EMEA
Wei Li C. is a Senior Safety Physician at Eisai EMEA since January 2017, with a strong background in pharmacovigilance and clinical research. Previously, Wei Li C. worked as a Clinical Research Physician at Richmond Pharmacology, overseeing early phase studies, including volunteer screening and safety assessments. Wei Li C. has also served as Company Director at WLC Locums, specializing in intensive care and acute medicine. Additional experience includes a role as Project Manager at Advantage Technoeconomics, focusing on health economics analysis, and training in anaesthesia and intensive care across multiple NHS trusts. Wei Li C. holds a Master of Science in Health Economics from The London School of Economics and Political Science and an MBChB from The University of Edinburgh, complemented by a Bachelor of Science in Microbiology and Infection from the same institution.
This person is not in any offices
Eisai EMEA
3 followers
At Eisai, everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational team working across a global network of R&D facilities, manufacturing sites and marketing subsidiaries. Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in a variety of therapeutic areas in which a high unmet medical need remains, including oncology and neurology. Our mission is clear; we strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy in everything we do. For more information about Eisai in the EMEA region please visit www.eisai.eu Our community guidelines can be found here: https://www.eisai.eu/wp-content/uploads/Community-guidelines-v1.0.pdf For more information about how Eisai processes your data, please refer to our privacy policy here: https://www.eisai.eu/privacy-policy/ --- November 2023 | EMEA-NON-23-00180